fda determin need set toler amount aph 3 rsquo ii consum agenc know reason protein would properti would distinguish toxicolog phosphoryl enzym food suppli also discuss aph 3 rsquo ii affect efficaci oral administ antibiot aph 3 rsquo ii rapidli digest normal condit gi tract even abnorm gastric condit aph 3 rsquo ii may rapidli digest amount atp avail food would allow small proport kanamycin neomycin inactiv therefor agenc conclud need requir qualiti control assur procedur ensur aph 3 rsquo ii level 0 1 percent total protein commerci tomato varieti third comment argu calgen provid data establish aph 3 rsquo ii would present tomato process extract edibl oil agenc exposur estim includ assumpt aph 3 rsquo ii would present process tomato fresh tomato even though high temperatur involv process inactiv enzym therefor process tomato product unlik contain enzymat activ aph 3 rsquo ii ref 18 addit well establish process procedur use extract edibl oil oilse crop extract signific amount protein ref 23 therefor exposur aph 3 rsquo ii obtain rapese oil cottonse oil would neglig ref 18 comment present inform contradict fda analysi conclus point 4 potenti side effect consumpt genet engin food one comment ask whether might side effect consumpt genet engin food whether side effect would short term long term anoth comment note food plant human exhibit complex unpredict behavior therefor safeti food substanc base thought gather empir evid comment point specif side effect genet engin food fda evalu safeti aph 3 rsquo ii determin safe propos use safeti assess fact base empir evid structur function aph 3 rsquo ii low level aph 3 rsquo ii occur food digest aph 3 rsquo ii inabl aph 3 rsquo ii interfer clinic use antibiot usual condit use antibiot 5 relev clinic studi sever comment note nation institut health nih gene therapi trial cancer patient infus cell contain kan r gene cite calgen strong evid safeti kan r gene provid littl inform concern safeti kan r gene aph 3 rsquo ii food one comment also note combin data vitro studi gene therapi studi inadequ basi safeti determin kan r gene aph 3 rsquo ii food million peopl might eat determin aph 3 rsquo ii safe propos food addit use fda reli nih gene therapi trial howev fda believ vitro degrad data provid import inform consid agenc part overal safeti assess kan r gene aph 3 rsquo ii discuss earlier document c possibl effect clinic efficaci oral administ kanamycin neomycin sever comment question whether presenc aph 3 rsquo ii tomato food might compromis clinic efficaci oral administ kanamycin neomycin one comment note calgen claim 76 800 peopl annual administ kanamycin neomycin oral argu peopl deserv put risk comment request calgen requir perform anim studi effect ingest aph 3 rsquo ii efficaci oral administ kanamycin neomycin comment assert aph 3 rsquo ii shown compromis clinic efficaci kanamycin neomycin food contain aph 3 rsquo ii appropri label comment observ ingest aph 3 rsquo ii would impair efficaci oral administ kanamycin neomycin antibiot rare administ oral kan r gene therefor good choic select marker gene fda agre calgen kanamycin neomycin rare administ oral primari clinic role oral administ neomycin lesser extent kanamycin cleans bowel microb prior bowel surgeri use rel minor sever side effect auditori nerv damag kidney damag may result antibiot absorb gi tract ref 38 discuss individu receiv oral kanamycin neomycin aph 3 rsquo ii inactiv acid environ stomach degrad digest enzym present gi tract import even patient receiv simultan treatment reduc stomach acid amount atp avail food would allow small fraction kanamycin neomycin inactiv comment advoc anim studi contradict directli indirectli fda analysi concern inactiv degrad aph 3 rsquo ii inform concern atp level fda therefor determin presenc aph 3 rsquo ii food compromis therapi oral administ kanamycin neomycin basi fda conclud neither anim studi effect ingest aph 3 rsquo ii efficaci antibiot special label food contain aph 3 rsquo ii patient receiv oral administ kanamycin neomycin necessari